Inicio>>Signaling Pathways>> Endocrinology and Hormones>> ROR/RAR/RXR>>CD 3254

CD 3254

Catalog No.GC17730

CD 3254 un agonista potente y selectivo del receptor X-retinoide (RXR).

Products are for research use only. Not for human use. We do not sell to patients.

CD 3254 Chemical Structure

Cas No.: 196961-43-0

Tamaño Precio Disponibilidad Cantidad
1mg
24,00 $
Disponible
5mg
90,00 $
Disponible
10mg
144,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CD3254 is a potent and selective agonist of Retinoid X receptors (RXRα).

Retinoid X receptors (RXRs) are nuclear receptors that act as ligand-dependent transcription factors and function as the homodimer or as heterodimers with other nuclear receptors, such as retinoic acid receptors (RARs), peroxisome proliferator-activated receptors (PPARs), or liver X receptors (LXRs). RXR plays essential roles in the regulation of glucose metabolism, lipid metabolism and immune response. Retinoid X receptors (RXRs) contains three family members including RARα, RARβ or RARγ receptors. RXRα belongs to the NR2B nuclear receptor family and primarily expressed in the liver, intestines, kidneys, and epidermis.

CD3254 and its’ analogue bexarotene have been reported as a treatment for cutaneous T-cell lymphoma (CTCL), despite the fact that treatment with CD3254 can evoke reactions by disturbing other RXR-heterodimer receptor pathways. Of the seven displayed novel exacerbates, all analogs animate RXR-controlled translation in mammalian 2 hybrid and RXRE-interceded tests, have equivalent or hoisted natural action in view of EC50 profiles, and hold comparative or enhanced apoptotic movement in CTCL assays contrasted with CD3254. Every single novel compound show selectivity for RXR and insignificant hybrid onto the retinoic corrosive receptor (RAR) contrasted with all-trans-retinoic corrosive, with select analogs likewise decreasing hindrance of other RXR-subordinate pathways (e.g., VDR-RXR) [1].

In vivo, CD3254 induced the phenotypes of malformations after 5 days exposure at low concentration (20 μg/l) to those after the 1st d exposure at high concentrations (50 and 100 μg/L) [2].

References:
Modeling, synthesis, and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene) and (E)-3-(3-(1,2,3,4-tetrahydro-1,1,4,4,6-pentamethylnaphthalen-7-yl)-4-hydroxyphenyl)acrylic acid (CD3254).  J Med Chem. 2013 Nov 14;56(21):8432-54. doi: 10.1021/jm4008517. Epub 2013 Nov 1.
Divergent teratogenicity of agonists of retinoid X receptors in embryos of zebrafish (Danio rerio).  Ecotoxicology. 2012 Jul;21(5):1465-75. doi: 10.1007/s10646-012-0900-9. Epub 2012 Apr 10.

Reseñas

Review for CD 3254

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CD 3254

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.